(NASDAQ: OCGN) has announced a significant development in its efforts to treat Stargardt disease, as the Data and Safety Monitoring Board (DSMB) has greenlit the enrollment for the second phase of ...
Using a gene signature technique to tailor chemotherapy for patients with early triple negative breast cancer shows promise ...
Calling the decision not to disclose the genetic results “certainly troubling” and “ethically fraught,” George Perry, editor ...